-

Cresco Labs Announces May Conference Participation

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced planned participation in upcoming conferences in May 2024.

19th Annual Needham Technology, Media & Consumer Conference, May 16, 2024, Virtual: Management will participate in a fireside chat and one-on-one meetings.

8th Annual Canaccord Global Cannabis Conference, May 23, 2024, New York City: Management will participate in panel and one-on-one meetings.

About Cresco Labs Inc.

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

Contacts

Media
Jason Erkes, Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
investors@crescolabs.com

General Inquiries
312-929-0993
info@crescolabs.com

Cresco Labs

CNSX:CL

Release Summary
Cresco Labs Announces May Conference Participation
Release Versions

Contacts

Media
Jason Erkes, Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
investors@crescolabs.com

General Inquiries
312-929-0993
info@crescolabs.com

More News From Cresco Labs

Cresco Labs Opens Sunnyside Tamarac, Expanding Patient Access in Broward County, Florida

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Tamarac, located at 6001 N University Drive in Tamarac, Fla. It is the Company’s 31st dispensary in Florida and 72nd nationwide. “Florida is the largest medical market in the country, and opening Sunnyside Tamarac reinforces our long-term commitment to serving patients across the state,” said Charlie Bachtell, CEO of Cresco Labs. “We’re...

Cresco Labs CEO: Rescheduling Marks Historic Shift for Cannabis Industry

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump’s action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act. “Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, ackn...

Cresco Labs Launches Flagship Flower Brand in Germany

CHICAGO--(BUSINESS WIRE)--Cresco Labs Launches Flower in Germany...
Back to Newsroom